Pathophysiological roles of chronic low-grade inflammation mediators in polycystic ovary syndrome
- PMID: 32617971
- DOI: 10.1002/jcp.29912
Pathophysiological roles of chronic low-grade inflammation mediators in polycystic ovary syndrome
Abstract
Polycystic ovary syndrome (PCOS) is the most common hormonal imbalance disease in reproductive-aged women. Its basic characteristics are ovulatory dysfunction and ovarian overproduction of androgens that lead to severe symptoms such as insulin resistance, hirsutism, infertility, and acne. Notwithstanding the disease burden, its underlying mechanisms remain unknown, and no causal therapeutic exists. In recent years, further studies showed that inflammation processes are involved in ovulation and play a key role in ovarian follicular dynamics. Visceral adipose tissue can cause inflammatory response and maintenance of the inflammation state in adipocytes by augmented production of inflammatory cytokines, monocyte chemoattractant proteins, and recruitment of the immune cell. Therefore, the PCOS can be related to a low-grade inflammation state and inflammatory markers. Investigating the inflammatory processes and mediators that contribute to the commencement and development of PCOS can be a critical step for better understanding the pathophysiology of the disease and its treatment through inhibition or control of related pathways. In the present review, we discuss the pathophysiological roles of chronic low-grade inflammation mediators including inflammasome-related cytokines, interleukin-1β (IL-1β), and IL-18 in PCOS development.
Keywords: IL-18; IL-1β; chronic low-grade inflammation; inflammasome; polycystic ovary syndrome.
© 2020 Wiley Periodicals LLC.
Similar articles
-
Chronic low-grade inflammation in polycystic ovary syndrome: is there a (patho)-physiological role for interleukin-1?Semin Immunopathol. 2019 Jul;41(4):447-459. doi: 10.1007/s00281-019-00737-4. Epub 2019 May 28. Semin Immunopathol. 2019. PMID: 31139895 Review.
-
Chronic Low Grade Inflammation in Pathogenesis of PCOS.Int J Mol Sci. 2021 Apr 6;22(7):3789. doi: 10.3390/ijms22073789. Int J Mol Sci. 2021. PMID: 33917519 Free PMC article. Review.
-
Association of metabolic and inflammatory markers with polycystic ovarian syndrome (PCOS): an update.Arch Gynecol Obstet. 2021 Mar;303(3):631-643. doi: 10.1007/s00404-020-05951-2. Epub 2021 Jan 13. Arch Gynecol Obstet. 2021. PMID: 33439300
-
Polycystic Ovary Syndrome as a Proinflammatory State: The Role of Adipokines.Curr Pharm Des. 2016;22(36):5535-5546. doi: 10.2174/1381612822666160726103133. Curr Pharm Des. 2016. PMID: 27464726 Review.
-
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.Endocr Pract. 2015 Nov;21(11):1291-300. doi: 10.4158/EP15748.DSC. Endocr Pract. 2015. PMID: 26509855
Cited by
-
Opportunities and challenges: interleukin-22 comprehensively regulates polycystic ovary syndrome from metabolic and immune aspects.J Ovarian Res. 2023 Jul 31;16(1):149. doi: 10.1186/s13048-023-01236-9. J Ovarian Res. 2023. PMID: 37525285 Free PMC article. Review.
-
Effects of Probiotic Intervention on Markers of Inflammation and Health Outcomes in Women of Reproductive Age and Their Children.Front Nutr. 2022 Jun 6;9:889040. doi: 10.3389/fnut.2022.889040. eCollection 2022. Front Nutr. 2022. PMID: 35734372 Free PMC article. Review.
-
Interleukin 10 (IL-10) gene variants and haplotypes in Tunisian women with polycystic ovary syndrome (PCOS): a case-control study.Mol Biol Rep. 2023 Oct;50(10):8089-8096. doi: 10.1007/s11033-023-08706-9. Epub 2023 Aug 4. Mol Biol Rep. 2023. PMID: 37541999
-
Short-chain fatty acid-butyric acid ameliorates granulosa cells inflammation through regulating METTL3-mediated N6-methyladenosine modification of FOSL2 in polycystic ovarian syndrome.Clin Epigenetics. 2023 May 13;15(1):86. doi: 10.1186/s13148-023-01487-9. Clin Epigenetics. 2023. PMID: 37179374 Free PMC article.
-
A Review of Clinical and Preclinical Studies on the Therapeutic Potential of Black Seeds (Nigella sativa) in the Management of Polycystic Ovarian Syndrome (PCOS).J Pharmacopuncture. 2023 Mar 31;26(1):1-9. doi: 10.3831/KPI.2023.26.1.1. J Pharmacopuncture. 2023. PMID: 37007297 Free PMC article. Review.
References
REFERENCES
-
- Abais, J. M., Xia, M., Zhang, Y., Boini, K. M., & Li, P.-L. (2015). Redox regulation of NLRP3 Inflammasomes: ROS as trigger or effector? Antioxidants & Redox Signaling, 22(13), 1111-1129.
-
- Amato, G., Conte, M., Mazziotti, G., Lalli, E., Vitolo, G., Tucker, A. T., … Izzo, A. (2003). Serum and follicular fluid cytokines in polycystic ovary syndrome during stimulated cycles. Obstetrics and Gynecology, 101(6), 1177-1182.
-
- Amini, L., Tehranian, N., Movahedin, M., Ramezani Tehrani, F., & Ziaee, S. (2015). Antioxidants and management of polycystic ovary syndrome in Iran: A systematic review of clinical trials. Iranian Journal of Reproductive Medicine, 13(1), 1-8.
-
- Asgharnia, M., Mirblook, F., & Ahmad Soltani, M. (2011). The prevalence of polycystic ovary syndrome (PCOS) in high school students in Rasht in 2009 according to NIH criteria. International Journal of Fertility & Sterility, 4(4), 156-159.
-
- Azziz, R., Woods, K. S., Reyna, R., Key, T. J., Knochenhauer, E. S., & Yildiz, B. O. (2004). The prevalence and features of the polycystic ovary syndrome in an unselected population. The Journal of Clinical Endocrinology & Metabolism, 89(6), 2745-2749.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous